NEUROCRINE BIOSCIENCES, INC. (NBIX) FY2026 YTD Q2 Statement of Cash Flows

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
NEUROCRINE BIOSCIENCES, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $282,200,000.00Net income → Operating adjustments reconciliation: $60,100,000.00Stock-based compensation → Operating adjustments reconciliation: $122,200,000.00Income tax assets and liabilities → Operating adjustments reconciliation: $60,200,000.00Other assets and liabilities, net → Operating adjustments reconciliation: $47,400,000.00Amortization of acquired intangible assets → Operating adjustments reconciliation: $16,500,000.00Depreciation → Operating adjustments reconciliation: $15,600,000.00Realized loss on sale of available-for-sale debt securities → Operating adjustments reconciliation: $5,200,000.00Non-cash lease expense → Operating adjustments reconciliation: $3,600,000.00Amortization of inventory fair-value step-up → Operating adjustments reconciliation: $3,000,000.00Operating adjustments reconciliation → Accounts receivable: $165,700,000.00Operating adjustments reconciliation → Deferred income taxes: $86,400,000.00Operating adjustments reconciliation → Gain on sale of business, net of transaction costs: $28,600,000.00Operating adjustments reconciliation → Changes in fair values of equity investments: $26,500,000.00Operating adjustments reconciliation → Accounts payable and accrued liabilities: $22,800,000.00Operating adjustments reconciliation → Inventory: $2,200,000.00Operating adjustments reconciliation → Accretion of discount on available-for-sale debt securities, net: $1,600,000.00Sales and maturities of available-for-sale debt securities → investing reconciliation: $2,527,500,000.00Proceeds from sale of business → investing reconciliation: $63,200,000.00investing reconciliation → Acquisition of business, net of cash acquired: $2,358,500,000.00investing reconciliation → Purchases of available-for-sale debt securities: $856,900,000.00investing reconciliation → Capital expenditures: $16,900,000.00Net cash used in financing activities → financing reconciliation: $22,700,000.00Proceeds from borrowings under revolving credit facility → financing reconciliation: $600,000,000.00Issuances of common stock under benefit plans → financing reconciliation: $108,400,000.00financing reconciliation → Repayments of borrowings under revolving credit facility: $600,000,000.00financing reconciliation → Repurchases of common stock: $66,000,000.00financing reconciliation → Taxes paid related to net share settlement of equity awards: $58,400,000.00financing reconciliation → Payment of debt issuance costs: $6,700,000.00Net cash used in investing activities → investing reconciliation: $641,600,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $721,000,000.00Net cash from operating activities → Cash sources and uses: $282,200,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $338,900,000.00Cash sources and uses → Net cash used in investing activities: $641,600,000.00Cash sources and uses → Net cash used in financing activities: $22,700,000.00Net income: $342,300,000.00Net income+$342.30 MStock-based compensation: $122,200,000.00Stock-based compensation+$122.20 MDepreciation: $15,600,000.00Depreciation expense+$15.60 MAmortization of inventory fair-value step-up: $3,000,000.00Inventory step-up amort.+$3.00 MRealized loss on sale of available-for-sale debt securities: $5,200,000.00AFS securities gain & loss+$5.20 MAccretion of discount on available-for-sale debt securities, net: -$1,600,000.00Investment discount & premium−$1.60 MAmortization of acquired intangible assets: $16,500,000.00Intangible amortization+$16.50 MChanges in fair values of equity investments: -$26,500,000.00Unrealized equity gain & loss−$26.50 MDeferred income taxes: -$86,400,000.00Deferred taxes & credits−$86.40 MAccounts receivable: -$165,700,000.00Accounts receivable−$165.70 MInventory: -$2,200,000.00Inventories−$2.20 MAccounts payable and accrued liabilities: -$22,800,000.00Payables & accrued liabilities−$22.80 MIncome tax assets and liabilities: $60,200,000.00Income tax balances+$60.20 MOther assets and liabilities, net: $47,400,000.00Other working capital, net+$47.40 MNon-cash lease expense: $3,600,000.00Operating lease amortization+$3.60 MGain on sale of business, net of transaction costs: -$28,600,000.00Disposal group gain & loss−$28.60 MOther: $0.00Net cash from operating activities: $282,200,000.00Operating cash+$282.20 MOperating adjustments reconciliation: $333,800,000.00Proceeds from borrowings under revolving credit facility: $600,000,000.00Credit line borrowings+$600.00 MRepayments of borrowings under revolving credit facility: -$600,000,000.00Credit line repayments−$600.00 MPayment of debt issuance costs: -$6,700,000.00Debt issuance costs−$6.70 MIssuances of common stock under benefit plans: $108,400,000.00Common stock issued+$108.40 MTaxes paid related to net share settlement of equity awards: -$58,400,000.00Stock-award tax withholding−$58.40 MRepurchases of common stock: -$66,000,000.00Common stock repurchases−$66.00 MNet cash used in financing activities: -$22,700,000.00. Cash required to fund net payments.Financing cash−$22.70 Mfinancing reconciliation: $731,100,000.00Purchases of available-for-sale debt securities: -$856,900,000.00AFS securities purchases−$856.90 MSales and maturities of available-for-sale debt securities: $2,527,500,000.00AFS securities proceeds+$2.53 BAcquisition of business, net of cash acquired: -$2,358,500,000.00Acquisitions, net of cash−$2.36 BCapital expenditures: -$16,900,000.00PP&E purchases−$16.90 MProceeds from sale of business: $63,200,000.00Business sales+$63.20 MNet cash used in investing activities: -$641,600,000.00. Cash required to fund net payments.Investing cash−$641.60 Minvesting reconciliation: $3,232,300,000.00Cash sources and uses: $1,003,200,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $721,000,000.00Beginning cash$721.00 MEnding cash: Cash, cash equivalents, and restricted cash: $338,900,000.00Ending cash$338.90 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$265.30 MOperating cash − cash spent on PP&ECash flow / Net income0.82×Operating cash flow ÷ net incomeNet cash change−$382.10 MEnding cash − beginning cash
Chart details

NEUROCRINE BIOSCIENCES, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
721,000,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
282,200,000 US dollars. Net cash provided.
Net income
342,300,000 US dollars
Stock-based compensation
122,200,000 US dollars
Depreciation
15,600,000 US dollars
Amortization of inventory fair-value step-up
3,000,000 US dollars
Realized loss on sale of available-for-sale debt securities
5,200,000 US dollars
Accretion of discount on available-for-sale debt securities, net
negative 1,600,000 US dollars
Amortization of acquired intangible assets
16,500,000 US dollars
Changes in fair values of equity investments
negative 26,500,000 US dollars
Deferred income taxes
negative 86,400,000 US dollars
Accounts receivable
negative 165,700,000 US dollars
Inventory
negative 2,200,000 US dollars
Accounts payable and accrued liabilities
negative 22,800,000 US dollars
Income tax assets and liabilities
60,200,000 US dollars
Other assets and liabilities, net
47,400,000 US dollars
Non-cash lease expense
3,600,000 US dollars
Gain on sale of business, net of transaction costs
negative 28,600,000 US dollars
Other
0 US dollars
Investing activities
negative 641,600,000 US dollars. Net cash used.
Purchases of available-for-sale debt securities
negative 856,900,000 US dollars
Sales and maturities of available-for-sale debt securities
2,527,500,000 US dollars
Acquisition of business, net of cash acquired
negative 2,358,500,000 US dollars
Capital expenditures
negative 16,900,000 US dollars
Proceeds from sale of business
63,200,000 US dollars
Financing activities
negative 22,700,000 US dollars. Net cash used.
Proceeds from borrowings under revolving credit facility
600,000,000 US dollars
Repayments of borrowings under revolving credit facility
negative 600,000,000 US dollars
Payment of debt issuance costs
negative 6,700,000 US dollars
Issuances of common stock under benefit plans
108,400,000 US dollars
Taxes paid related to net share settlement of equity awards
negative 58,400,000 US dollars
Repurchases of common stock
negative 66,000,000 US dollars
Operating adjustment reconciliation
333,800,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
731,100,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
3,232,300,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Jun 30, 2026
338,900,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
1,003,200,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 382,100,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
0.82×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
282,200,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
16,900,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
265,300,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income exceeds operating cash. The diagram allocates $282.20M of net income directly to operating cash and $60.10M to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 282,200,000 US dollars minus 16,900,000 US dollars equals 265,300,000 US dollars.
NEUROCRINE BIOSCIENCES, INC. (NBIX) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!